DGX Q1 Earnings Call: Acquisitions, Advanced Diagnostics, and Operational Initiatives Drive Growth

Healthcare diagnostics company Quest Diagnostics (NYSE: DGX) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 12.1% year on year to $2.65 billion. The company expects the full year’s revenue to be around $10.78 billion, close to analysts’ estimates. Its non-GAAP profit of $2.21 per share was 2.9% above analysts’ consensus estimates.

Is now the time to buy DGX? Find out in our full research report (it’s free).

StockStory’s Take

Quest Diagnostics delivered notable financial results in the first quarter, with management attributing revenue growth to a combination of recent acquisitions and higher demand for advanced diagnostics. CEO Jim Davis emphasized that large enterprise accounts, expanded health plan access, and increased adoption of the company's novel tests, such as the PFAS "Forever Chemicals" test, were significant contributors. Davis also highlighted a rebound in testing volumes following weather-related impacts early in the quarter, as well as growth through new health plan partnerships and advanced diagnostics in cardiometabolic, autoimmune, and brain health categories.

Looking ahead, management reaffirmed full-year guidance and pointed to several factors shaping their outlook. Investments in automation, artificial intelligence, and quality management are expected to drive operational efficiencies, while the company continues to monitor potential regulatory changes and inflationary pressures. CFO Sam Samad explained that the company's guidance assumes manageable exposure to tariffs and ongoing productivity improvements through initiatives like Project Nova and Invigorate. "We are reaffirming our revenue and adjusted EPS guidance for the full year," Davis stated, pointing to continued confidence in the company’s strategic direction.

Key Insights from Management’s Remarks

Quest Diagnostics’ first quarter results were shaped by acquisitions, growing demand for advanced diagnostics, operational improvements, and selective expansion in enterprise and hospital partnerships.

• Acquisitions and enterprise accounts: Management cited recent acquisitions, including LifeLabs and select Fresenius Medical Care lab assets, as key to revenue growth, particularly in the physician channel. These deals have brought new volumes and expanded Quest’s footprint in North America.
• Advanced diagnostics momentum: The company’s advanced diagnostics portfolio, spanning cardiometabolic, autoimmune, brain health, oncology, and women’s health, experienced double-digit growth. Notable product launches included an updated Alzheimer’s blood test panel and a self-collection HPV screening option for cervical cancer at the point of care.
• Health plan and network expansion: New health plan partnerships, such as being named to the Optum Health preferred lab network, allowed Quest to access a wider pool of physicians and patients, further boosting test volume and reach.
• Operational investments: Management continued investments in laboratory automation, robotics, and artificial intelligence, aiming to improve productivity, quality, and both customer and employee experiences. The Project Nova initiative, in collaboration with Google Cloud, was highlighted as a step toward modernizing order-to-cash processes and data management.
• International and regulatory developments: Expansion in Canada via LifeLabs and selective international reference testing contributed to the global growth strategy. Management also addressed the favorable court decision on FDA lab-developed test (LDT) regulation, stating ongoing investment in quality management systems to navigate diverse regulatory environments.

Drivers of Future Performance

Management’s outlook for the remainder of the year centers on operational efficiency, expanded advanced diagnostics offerings, and the ability to mitigate external risks such as tariffs and labor costs.

• Ongoing productivity initiatives: Quest expects to achieve annual cost savings and productivity improvements through its Invigorate program and Project Nova, which are designed to streamline processes and leverage automation and AI.
• Expansion of advanced diagnostics: The company will focus on driving double-digit growth in advanced diagnostics—especially in cardiometabolic, autoimmune, and oncology segments—which management believes will support higher-margin revenue streams.
• Navigating external risks: Management identified manageable exposure to tariff-related supply costs and planned wage inflation, emphasizing fixed multiyear supplier contracts and proactive sourcing strategies to protect margins.

Top Analyst Questions

• Luke Sergott (Barclays): Asked about organic volume trends and the impact of weather; management explained that after adjusting for weather and calendar effects, volume growth was consistent with recent quarters and rebounded strongly in late March and April.
• Kevin Caliendo (UBS): Inquired about the company’s exposure to tariffs and supply chain risks; management clarified less than 1% of supply spend is sourced from China and most contracts are long-term, reducing tariff exposure.
• Patrick Donnelly (Citi): Sought details on margin pacing and LifeLabs performance; management said margin trends follow historical seasonality and LifeLabs is progressing toward corporate average margins within two to three years.
• Noah Kava (Jefferies): Asked about commercial uptake and reimbursement pathways for the Haystack MRD oncology test; management reported early adoption, ongoing reimbursement submissions, and continued clinical evidence development.
• David Westenberg (Piper Sandler): Questioned the financial impact of the Google Cloud collaboration and use of generative AI; management said benefits include improved data efficiency, faster analytics, and future AI-driven tools for customers and employees.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will monitor (1) the pace of margin improvement as Quest integrates recent acquisitions and drives operational savings, (2) the adoption of new advanced diagnostics and progress of key product launches such as the Alzheimer’s and self-collect HPV tests, and (3) ongoing developments in regulatory policy and reimbursement, particularly surrounding tariffs, LDTs, and major government payer programs. The execution of Project Nova and the impact of automation and AI on productivity will also be important indicators of Quest’s ability to sustain growth.

Quest currently trades at a forward P/E ratio of 17.9×. Should you load up, cash out, or stay put? See for yourself in our free research report.

Stocks That Overcame Trump’s 2018 Tariffs

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.